Identification

Name
Ribostamycin
Accession Number
DB03615  (EXPT02786)
Type
Small Molecule
Groups
Approved
Description

A broad-spectrum antimicrobial isolated from Streptomyces ribosifidicus. Ribostamycin, along with other aminoglycosides with the DOS (2-deoxystreptamine) subunit, is an important broad-spectrum antibiotic with important use against human immunodeficiency virus and is considered a critically important antimicrobial by the World Health Organization.

Structure
Thumb
Synonyms
  • 5-Amino-2-Aminomethyl-6-[4,6-Diamino-2-(3,4-Dihydroxy-5-Hydroxymethyl-Tetrahydro-Furan-2-Yloxy)-3-Hydroxy-Cyclohexyloxy]-Tetrahydro-Pyran-3,4-Diol
  • Ribastamin
  • RIO
  • Vistamycin
  • Xylostacin
  • Xylostasin
External IDs
Antibiotic SF 733 / SF-733
Product Ingredients
IngredientUNIICASInChI Key
Ribostamycin sulfateQFN1QU7PEN 53797-35-6Not applicable
Categories
UNII
2Q5JOU7T53
CAS number
25546-65-0
Weight
Average: 454.4727
Monoisotopic: 454.227493328
Chemical Formula
C17H34N4O10
InChI Key
NSKGQURZWSPSBC-VVPCINPTSA-N
InChI
InChI=1S/C17H34N4O10/c18-2-6-10(24)12(26)8(21)16(28-6)30-14-5(20)1-4(19)9(23)15(14)31-17-13(27)11(25)7(3-22)29-17/h4-17,22-27H,1-3,18-21H2/t4-,5+,6-,7-,8-,9+,10-,11-,12-,13-,14-,15-,16-,17+/m1/s1
IUPAC Name
(2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-{[(1R,2R,3S,4R,6S)-4,6-diamino-2-{[(2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}-3-hydroxycyclohexyl]oxy}oxane-3,4-diol
SMILES

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action

Aminoglycosides work by binding to the bacterial 30S ribosomal subunit (some work by binding to the 50S subunit), inhibiting the translocation of the peptidyl-tRNA from the A-site to the P-site and also causing misreading of mRNA, leaving the bacterium unable to synthesize proteins vital to its growth. However, their exact mechanism of action is not fully known.

TargetActionsOrganism
UProtein disulfide-isomeraseNot AvailableHuman
U30S ribosomal protein S12Not AvailableEscherichia coli (strain K12)
UAminoglycoside N(6')-acetyltransferase type 1Not AvailableSalmonella enteritidis
UAminoglycoside 2'-N-acetyltransferaseNot AvailableMycobacterium tuberculosis
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
  • Enteric bacteria and other eubacteria
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AceclofenacAceclofenac may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
AcemetacinAcemetacin may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Experimental
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Ribostamycin.Approved
AcetyldigoxinThe serum concentration of Acetyldigoxin can be decreased when it is combined with Ribostamycin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Vet Approved
AdapaleneAdapalene may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
AlclofenacAlclofenac may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Withdrawn
AlcuroniumRibostamycin may increase the respiratory depressant activities of Alcuronium.Experimental
Alendronic acidRibostamycin may increase the hypocalcemic activities of Alendronic acid.Approved
AlminoprofenAlminoprofen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Experimental
AmdinocillinThe serum concentration of Ribostamycin can be decreased when it is combined with Amdinocillin.Withdrawn
AmoxicillinThe serum concentration of Ribostamycin can be decreased when it is combined with Amoxicillin.Approved, Vet Approved
Amphotericin BAmphotericin B may increase the nephrotoxic activities of Ribostamycin.Approved, Investigational
AmpicillinThe serum concentration of Ribostamycin can be decreased when it is combined with Ampicillin.Approved, Vet Approved
AndrographolideAndrographolide may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
AnisodamineAnisodamine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
AntipyrineAntipyrine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
ApocyninApocynin may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
ApremilastApremilast may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
AspoxicillinThe serum concentration of Ribostamycin can be decreased when it is combined with Aspoxicillin.Experimental
AtracuriumRibostamycin may increase the respiratory depressant activities of Atracurium.Experimental
Atracurium besylateRibostamycin may increase the respiratory depressant activities of Atracurium besylate.Approved
AzapropazoneAzapropazone may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Withdrawn
AzelastineAzelastine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
AzidocillinThe serum concentration of Ribostamycin can be decreased when it is combined with Azidocillin.Approved
AzlocillinThe serum concentration of Ribostamycin can be decreased when it is combined with Azlocillin.Approved
BacampicillinThe serum concentration of Ribostamycin can be decreased when it is combined with Bacampicillin.Approved
BalsalazideBalsalazide may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Ribostamycin.Investigational
BendazacBendazac may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Experimental
BenorilateBenorilate may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Experimental
BenoxaprofenBenoxaprofen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Withdrawn
Benzathine benzylpenicillinThe serum concentration of Ribostamycin can be decreased when it is combined with Benzathine benzylpenicillin.Approved, Vet Approved
BenzylpenicillinThe serum concentration of Ribostamycin can be decreased when it is combined with Benzylpenicillin.Approved, Vet Approved
Benzylpenicilloyl PolylysineThe serum concentration of Ribostamycin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
BevoniumBevonium may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Experimental
Botulinum Toxin Type ARibostamycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BRibostamycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved
BromfenacBromfenac may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
BucillamineBucillamine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
BufexamacBufexamac may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Experimental
BumadizoneBumadizone may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Ribostamycin.Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Ribostamycin.Approved
Carbaspirin calciumCarbaspirin calcium may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Experimental
CarbenicillinThe serum concentration of Ribostamycin can be decreased when it is combined with Carbenicillin.Approved
Carbenicillin indanylThe serum concentration of Ribostamycin can be decreased when it is combined with Carbenicillin indanyl.Approved
CarboplatinRibostamycin may increase the ototoxic activities of Carboplatin.Approved
CarfecillinThe serum concentration of Ribostamycin can be decreased when it is combined with Carfecillin.Experimental
CarprofenCarprofen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Experimental
CelecoxibCelecoxib may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
ChloroquineChloroquine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Vet Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
CisatracuriumRibostamycin may increase the respiratory depressant activities of Cisatracurium.Experimental
Cisatracurium besylateRibostamycin may increase the respiratory depressant activities of Cisatracurium besylate.Approved
CisplatinCisplatin may increase the nephrotoxic activities of Ribostamycin.Approved
Clodronic AcidRibostamycin may increase the hypocalcemic activities of Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinClonixin may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
CloxacillinThe serum concentration of Ribostamycin can be decreased when it is combined with Cloxacillin.Approved, Vet Approved
ColistimethateRibostamycin may increase the nephrotoxic activities of Colistimethate.Approved, Vet Approved
CurcuminCurcumin may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
CyclacillinThe serum concentration of Ribostamycin can be decreased when it is combined with Cyclacillin.Approved
CyclosporineRibostamycin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CymarinThe serum concentration of Cymarin can be decreased when it is combined with Ribostamycin.Experimental
D-LimoneneD-Limonene may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
DecamethoniumRibostamycin may increase the respiratory depressant activities of Decamethonium.Approved
DeslanosideThe serum concentration of Deslanoside can be decreased when it is combined with Ribostamycin.Approved
DiclofenacDiclofenac may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Vet Approved
DicloxacillinThe serum concentration of Ribostamycin can be decreased when it is combined with Dicloxacillin.Approved, Vet Approved
DifenpiramideDifenpiramide may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Experimental
DiflunisalDiflunisal may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Ribostamycin.Approved
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Ribostamycin.Approved
Domoic AcidRibostamycin may increase the respiratory depressant activities of Domoic Acid.Experimental
Doxacurium chlorideRibostamycin may increase the respiratory depressant activities of Doxacurium chloride.Approved
DroxicamDroxicam may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
DuvelisibDuvelisib may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
E-6201E-6201 may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
EpicillinThe serum concentration of Ribostamycin can be decreased when it is combined with Epicillin.Experimental
EpirizoleEpirizole may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Ribostamycin.Approved
EtanerceptEtanercept may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
EthenzamideEthenzamide may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Experimental
Etidronic acidRibostamycin may increase the hypocalcemic activities of Etidronic acid.Approved
EtodolacEtodolac may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
EtoricoxibEtoricoxib may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
exisulindexisulind may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
FelbinacFelbinac may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Experimental
FenbufenFenbufen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
FenoprofenFenoprofen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
FentiazacFentiazac may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Experimental
FeprazoneFeprazone may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Experimental
Ferulic acidFerulic acid may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Experimental
FloctafenineFloctafenine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Withdrawn
FlucloxacillinThe serum concentration of Ribostamycin can be decreased when it is combined with Flucloxacillin.Approved
FlunixinFlunixin may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Experimental
FlurbiprofenFlurbiprofen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
FoscarnetFoscarnet may increase the nephrotoxic activities of Ribostamycin.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Ribostamycin.Approved, Vet Approved
GallamineRibostamycin may increase the respiratory depressant activities of Gallamine.Experimental
Gallamine TriethiodideRibostamycin may increase the respiratory depressant activities of Gallamine Triethiodide.Approved
GitoformateThe serum concentration of Gitoformate can be decreased when it is combined with Ribostamycin.Experimental
GuacetisalGuacetisal may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Experimental
HigenamineHigenamine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
IbandronateRibostamycin may increase the hypocalcemic activities of Ibandronate.Approved, Investigational
IbuprofenIbuprofen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
IbuproxamIbuproxam may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Withdrawn
IcatibantIcatibant may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
Imidazole salicylateImidazole salicylate may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Experimental
IndobufenIndobufen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
IndomethacinIndomethacin may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
IndoprofenIndoprofen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Withdrawn
IsoxicamIsoxicam may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Withdrawn
KebuzoneKebuzone may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Experimental
KetoprofenKetoprofen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Vet Approved
KetorolacKetorolac may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
Lanatoside CThe serum concentration of Lanatoside C can be decreased when it is combined with Ribostamycin.Experimental
LeflunomideLeflunomide may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
LisofyllineLisofylline may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
LonazolacLonazolac may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Experimental
LornoxicamLornoxicam may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
LoxoprofenLoxoprofen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
LumiracoxibLumiracoxib may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
MannitolMannitol may increase the nephrotoxic activities of Ribostamycin.Approved, Investigational
MasoprocolMasoprocol may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
MecamylamineRibostamycin may increase the neuromuscular blocking activities of Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
MeloxicamMeloxicam may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Vet Approved
MesalazineMesalazine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
MetamizoleMetamizole may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Withdrawn
MetampicillinThe serum concentration of Ribostamycin can be decreased when it is combined with Metampicillin.Experimental
MeticillinThe serum concentration of Ribostamycin can be decreased when it is combined with Meticillin.Approved
MetildigoxinThe serum concentration of Metildigoxin can be decreased when it is combined with Ribostamycin.Experimental
MetocurineRibostamycin may increase the respiratory depressant activities of Metocurine.Approved
Metocurine IodideRibostamycin may increase the respiratory depressant activities of Metocurine Iodide.Withdrawn
MezlocillinThe serum concentration of Ribostamycin can be decreased when it is combined with Mezlocillin.Approved
MivacuriumRibostamycin may increase the respiratory depressant activities of Mivacurium.Approved
MizoribineMizoribine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
MofebutazoneMofebutazone may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Experimental
Mycophenolate mofetilMycophenolate mofetil may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
NabumetoneNabumetone may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
NafamostatNafamostat may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
NafcillinThe serum concentration of Ribostamycin can be decreased when it is combined with Nafcillin.Approved
NaftifineNaftifine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
NaproxenNaproxen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Vet Approved
NeosaxitoxinRibostamycin may increase the respiratory depressant activities of Neosaxitoxin.Investigational
NepafenacNepafenac may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
NifenazoneNifenazone may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Experimental
Niflumic AcidNiflumic Acid may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
NimesulideNimesulide may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Withdrawn
NitroaspirinNitroaspirin may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
OleandrinThe serum concentration of Oleandrin can be decreased when it is combined with Ribostamycin.Experimental
OlopatadineOlopatadine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
OlsalazineOlsalazine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
OrgoteinOrgotein may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Vet Approved
OuabainThe serum concentration of Ouabain can be decreased when it is combined with Ribostamycin.Approved
OxacillinThe serum concentration of Ribostamycin can be decreased when it is combined with Oxacillin.Approved
OxaprozinOxaprozin may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
OxyphenbutazoneOxyphenbutazone may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Withdrawn
PamidronateRibostamycin may increase the hypocalcemic activities of Pamidronate.Approved
PancuroniumRibostamycin may increase the respiratory depressant activities of Pancuronium.Approved
ParecoxibParecoxib may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
ParthenolideParthenolide may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
PenamecillinThe serum concentration of Ribostamycin can be decreased when it is combined with Penamecillin.Experimental
PenimepicyclineThe serum concentration of Ribostamycin can be decreased when it is combined with Penimepicycline.Experimental
PeruvosideThe serum concentration of Peruvoside can be decreased when it is combined with Ribostamycin.Experimental
PhenoxymethylpenicillinThe serum concentration of Ribostamycin can be decreased when it is combined with Phenoxymethylpenicillin.Approved, Vet Approved
PhenylbutazonePhenylbutazone may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ribostamycin.Approved
PimecrolimusPimecrolimus may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
PipecuroniumRibostamycin may increase the respiratory depressant activities of Pipecuronium.Approved
PiperacillinThe serum concentration of Ribostamycin can be decreased when it is combined with Piperacillin.Approved
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Ribostamycin.Experimental
PirfenidonePirfenidone may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
PiroxicamPiroxicam may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
PirprofenPirprofen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Experimental
PivampicillinThe serum concentration of Ribostamycin can be decreased when it is combined with Pivampicillin.Approved
PivmecillinamThe serum concentration of Ribostamycin can be decreased when it is combined with Pivmecillinam.Approved
PranoprofenPranoprofen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Experimental
Procaine benzylpenicillinThe serum concentration of Ribostamycin can be decreased when it is combined with Procaine benzylpenicillin.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Experimental
PropacetamolPropacetamol may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
PropicillinThe serum concentration of Ribostamycin can be decreased when it is combined with Propicillin.Experimental
PropyphenazonePropyphenazone may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Experimental
ProquazoneProquazone may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Experimental
ProscillaridinThe serum concentration of Proscillaridin can be decreased when it is combined with Ribostamycin.Experimental
PTC299PTC299 may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
PyrantelRibostamycin may increase the respiratory depressant activities of Pyrantel.Approved, Vet Approved
RapacuroniumRibostamycin may increase the respiratory depressant activities of Rapacuronium.Withdrawn
ResveratrolResveratrol may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Experimental, Investigational
RisedronateRibostamycin may increase the hypocalcemic activities of Risedronate.Approved, Investigational
RocuroniumRibostamycin may increase the respiratory depressant activities of Rocuronium.Approved
RofecoxibRofecoxib may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational, Withdrawn
SalicylamideSalicylamide may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
Salicylic acidSalicylic acid may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Vet Approved
SalsalateSalsalate may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
SemapimodSemapimod may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
SeratrodastSeratrodast may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
SerrapeptaseSerrapeptase may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
SRT501SRT501 may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
SuccinylcholineRibostamycin may increase the respiratory depressant activities of Succinylcholine.Approved
SulbactamThe serum concentration of Ribostamycin can be decreased when it is combined with Sulbactam.Approved
SulbenicillinThe serum concentration of Ribostamycin can be decreased when it is combined with Sulbenicillin.Experimental
SulfasalazineSulfasalazine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
SulindacSulindac may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
SultamicillinThe serum concentration of Ribostamycin can be decreased when it is combined with Sultamicillin.Investigational
SuprofenSuprofen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Experimental
TalampicillinThe serum concentration of Ribostamycin can be decreased when it is combined with Talampicillin.Experimental
TarenflurbilTarenflurbil may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
TazobactamThe serum concentration of Ribostamycin can be decreased when it is combined with Tazobactam.Approved
Technetium Tc-99m etidronateRibostamycin may increase the hypocalcemic activities of Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateRibostamycin may increase the hypocalcemic activities of Technetium Tc-99m medronate.Approved
TenidapTenidap may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Experimental
Tenofovir disoproxilThe serum concentration of Ribostamycin can be increased when it is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamTenoxicam may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
TepoxalinTepoxalin may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Vet Approved
TeriflunomideTeriflunomide may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
Tiaprofenic acidTiaprofenic acid may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
TicarcillinThe serum concentration of Ribostamycin can be decreased when it is combined with Ticarcillin.Approved, Vet Approved
Tiludronic acidRibostamycin may increase the hypocalcemic activities of Tiludronic acid.Approved, Vet Approved
TinoridineTinoridine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
Tolfenamic AcidTolfenamic Acid may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
TolmetinTolmetin may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Ribostamycin.Approved
TranilastTranilast may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
TribenosideTribenoside may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Experimental
TriptolideTriptolide may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational
TubocurarineRibostamycin may increase the respiratory depressant activities of Tubocurarine.Approved
ValdecoxibValdecoxib may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Investigational, Withdrawn
VancomycinVancomycin may increase the nephrotoxic activities of Ribostamycin.Approved
VecuroniumRibostamycin may increase the respiratory depressant activities of Vecuronium.Approved
ZaltoprofenZaltoprofen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
ZileutonZileuton may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
Zoledronic acidRibostamycin may increase the hypocalcemic activities of Zoledronic acid.Approved
ZomepiracZomepirac may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

Eiichi Akita, Tsutomu Tsuchiya, Shinichi Kondo, Shuntaro Yasuda, Sumio Umezawa, Hamao Umezawa, "1-N-((S)-.alpha.-substituted-.omega.-aminoacyl)-neamine or -ribostamycin and the production thereof." U.S. Patent US4008218, issued February, 1974.

US4008218
General References
Not Available
External Links
KEGG Compound
C01759
ChemSpider
30581
ChEBI
45257
ChEMBL
CHEMBL221572
Therapeutic Targets Database
DNC001211
HET
RIO
ATC Codes
J01GB10 — Ribostamycin
AHFS Codes
Not Available
PDB Entries
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4RecruitingTreatmentSarcoidosis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)193.5 °CPhysProp
pKa7.7MERCK INDEX (1996)
Predicted Properties
PropertyValueSource
Water Solubility88.7 mg/mLALOGPS
logP-2.9ALOGPS
logP-6.4ChemAxon
logS-0.71ALOGPS
pKa (Strongest Acidic)12.19ChemAxon
pKa (Strongest Basic)9.93ChemAxon
Physiological Charge4ChemAxon
Hydrogen Acceptor Count14ChemAxon
Hydrogen Donor Count10ChemAxon
Polar Surface Area262.38 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity100.17 m3·mol-1ChemAxon
Polarizability44.29 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8617
Blood Brain Barrier-0.9659
Caco-2 permeable-0.7502
P-glycoprotein substrateNon-substrate0.5164
P-glycoprotein inhibitor INon-inhibitor0.8023
P-glycoprotein inhibitor IINon-inhibitor0.8764
Renal organic cation transporterNon-inhibitor0.7886
CYP450 2C9 substrateNon-substrate0.8231
CYP450 2D6 substrateNon-substrate0.8041
CYP450 3A4 substrateNon-substrate0.6473
CYP450 1A2 substrateNon-inhibitor0.9157
CYP450 2C9 inhibitorNon-inhibitor0.9147
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9034
CYP450 3A4 inhibitorNon-inhibitor0.9471
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8446
Ames testNon AMES toxic0.6934
CarcinogenicityNon-carcinogens0.9505
BiodegradationNot ready biodegradable0.8587
Rat acute toxicity1.4850 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9728
hERG inhibition (predictor II)Non-inhibitor0.81
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Protein heterodimerization activity
Specific Function
This multifunctional protein catalyzes the formation, breakage and rearrangement of disulfide bonds. At the cell surface, seems to act as a reductase that cleaves disulfide bonds of proteins attach...
Gene Name
P4HB
Uniprot ID
P07237
Uniprot Name
Protein disulfide-isomerase
Molecular Weight
57115.795 Da
References
  1. Horibe T, Nagai H, Sakakibara K, Hagiwara Y, Kikuchi M: Ribostamycin inhibits the chaperone activity of protein disulfide isomerase. Biochem Biophys Res Commun. 2001 Dec 21;289(5):967-72. [PubMed:11741285 ]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Unknown
General Function
Trna binding
Specific Function
With S4 and S5 plays an important role in translational accuracy.Interacts with and stabilizes bases of the 16S rRNA that are involved in tRNA selection in the A site and with the mRNA backbone. Lo...
Gene Name
rpsL
Uniprot ID
P0A7S3
Uniprot Name
30S ribosomal protein S12
Molecular Weight
13736.995 Da
Kind
Protein
Organism
Salmonella enteritidis
Pharmacological action
Unknown
General Function
Protein homodimerization activity
Specific Function
Catalyzes the transfer of an acetyl group from acetyl-CoA to the 6'-amino group of aminoglycoside molecules conferring resistance to antibiotics containing the purpurosamine ring including amikacin...
Gene Name
Not Available
Uniprot ID
Q9R381
Uniprot Name
Aminoglycoside N(6')-acetyltransferase type 1
Molecular Weight
16361.42 Da
Kind
Protein
Organism
Mycobacterium tuberculosis
Pharmacological action
Unknown
General Function
May catalyze the coenzyme A-dependent acetylation of the 2' hydroxyl or amino group of a broad spectrum of aminoglycosides and confer resistance to aminoglycosides (By similarity). In vitro assays show no significant increase of resistance to aminoglycosides, possibly due to low expression in a heterologous system (PubMed:9159528).
Specific Function
Aminoglycoside 2'-n-acetyltransferase activity
Gene Name
aac
Uniprot ID
P9WQG9
Uniprot Name
Aminoglycoside 2'-N-acetyltransferase
Molecular Weight
20037.53 Da

Enzymes

Kind
Protein
Organism
Mycobacterium tuberculosis
Pharmacological action
Unknown
General Function
May catalyze the coenzyme A-dependent acetylation of the 2' hydroxyl or amino group of a broad spectrum of aminoglycosides and confer resistance to aminoglycosides (By similarity). In vitro assays show no significant increase of resistance to aminoglycosides, possibly due to low expression in a heterologous system (PubMed:9159528).
Specific Function
Aminoglycoside 2'-n-acetyltransferase activity
Gene Name
aac
Uniprot ID
P9WQG9
Uniprot Name
Aminoglycoside 2'-N-acetyltransferase
Molecular Weight
20037.53 Da

Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 05:24